Research Article

Delivery of miR-654-5p via SonoVue Microbubble Ultrasound Inhibits Proliferation, Migration, and Invasion of Vascular Smooth Muscle Cells and Arterial Thrombosis and Stenosis through Targeting TCF21

Tao Wang, Xiaoqiang Tang, Yong Zhang, Xiaoqin Wang, Haifeng Shi, Ruohan Yin, and Changjie Pan

The Department of Radiology, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, China

Correspondence should be addressed to Changjie Pan; panchangjie@njmu.edu.cn

Received 28 April 2022; Revised 11 June 2022; Accepted 21 June 2022; Published 19 July 2022

Academic Editor: Anwen Shao

Copyright © 2022 Tao Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Abnormal proliferation of vascular smooth muscle cells (VSMCs) is an important cause of vascular stenosis. The study explored the mechanism of inhibition of vascular stenosis through the molecular mechanism of smooth muscle cell phenotype transformation.

Methods. Coronary heart disease-related genes were screened by bioinformatics, and the target genes of miR-654-5p were predicted by dual-luciferase method and immunofluorescence method. miR-654-5p mimic stimulation and transfection of TCF21 and MTAP into cells. SonoVue microbubble sonication was used to deliver miR-654-5p into cells. Cell proliferation, migration, and invasion were detected by CCK-8, wound scratch, and Transwell. HE and IHC staining were performed to study the effect of miR-654-5p delivery via SonoVue microbubble ultrasound on vessel stenosis in a model of arterial injury. Gene expression was determined by qRT-PCR and WB.

Results. TCF21 and MTAP were predicted as the target genes of miR-654-5p. Cytokines induced smooth muscle cell proliferation, migration, and invasion and promoted miR-654-5p downregulation; noticeably, downregulated miR-654-5p was positively associated with the cell proliferation and migration. Overexpression of TCF21 promoted proliferation, invasion, and migration, and mimic reversed such effects. miR-654-5p overexpression delivered by SonoVue microbubble ultrasound inhibited proliferation, migration, and invasion of cells. Moreover, in arterial injury model, we found that SonoVue microbubble ultrasound transmitted miR-654-5p into the arterial wall to inhibit arterial thrombosis and stenosis, while TCF21 was inhibited.

Conclusion. Ultrasound delivery of miR-654-5p via SonoVue microbubbles was able to inhibit arterial thrombosis and stenosis by targeting TCF21.

1. Introduction

Atherosclerosis is a systematic and progressive pathological process that can occur in any part of blood vessels in the human body and is the most frequently seen in arteries [1]. Atherosclerosis causes noninflammatory, degenerative, and proliferative lesions of blood vessels, increasing the incidence of cardiovascular and cerebrovascular diseases [2–4]. Pathological diagnosis showed that intravascular thrombosis and stenosis are the main characteristics of atherosclerosis [5]. In recent years, percutaneous coronary intervention (PCI) is often applied to treat patients with coronary artery stenosis caused by atherosclerosis [6]. However, some patients have vascular stenosis recurrence in the lesions, which not only reduces the therapeutic effect of PCI but also increases the possibility of atherosclerosis and recurrence [7].

At present, it is believed that the abnormal proliferation of the neointimal membrane is the pathophysiological basis of restenosis after PCI during the process of injured vascular repair [8]. The enhancement of proliferation and migration of vascular smooth muscle cells (VSMCs) is an important cause of neointimal hyperplasia after vascular injury [9, 10]. The high elasticity of VSMCs enables them to rapidly
adapt to changes in the surrounding environment, especially when stimulated by extracellular matrix components, cytokines, shear stress, and other factors. VSMCs significantly reduce the expression of their differentiation markers, thereby increasing proliferation, the ability to migrate and synthesize the extracellular matrix involved in neointima formation [11, 12]. Accordingly, the expression of VSMC phenotype plays an important role in vascular diseases. Therefore, understanding the molecular mechanism of VSMC phenotype transformation possibly provides a regulatory target for the prevention and treatment of restenosis after PCI.

In recent years, data indicated that microRNAs (miRNAs) play an important regulatory role in a variety of cardiovascular and cerebrovascular diseases induced by atherosclerotic plaques [13, 14]. Our results indicated that miR-654-5p was expressed in patients with coronary heart disease through bioinformatics analysis, but whether miR-654-5p was involved in the formation of atherosclerotic plaques has not been reported yet. Therefore, this study further explored miR-654-5p, whether 654-5p is involved in the phenotypic transformation process of VSMCs and the degree of vascular stenosis, so as to determine the biological significance of miR-654-5p in regulating atherosclerotic plaques.

TCF21 was predicted as a target gene of miR-654-5p by TargetScan and miRWalk. A study found that TCF21 plays an important role in the activation of proinflammatory gene expression in coronary artery smooth muscle cells [15]. However, to the best of our knowledge, there is currently no research conducted on the molecular mechanism of the regulation of miR-654-5p targeting TCF21 in smooth muscle cell phenotype transformation. Thus, the current study used ultrasound microbubble contrast agent to deliver miR-654-5p into inflammatory-stimulated smooth muscle cells and carotid injury model in rats and explored the impact of the regulation of miR-654-5p in atherosclerotic plaque through targeting TCF21.

2. Methods

2.1. Data Extraction from the GEO Database. Terms "coronary artery disease" and "miRNAs" were retrieved in the GEO datasets (https://www.ncbi.nlm.nih.gov/gds) to obtain the datasets of differentially expressed miRNAs. We obtained the dataset GSE59421 as the basis for differentially expressed miRNA in patients with vascular embolism in the current study. Next, the differentially expressed genes in patients with coronary artery disease and healthy controls were selected to further determine differentially expressed genes, and the intersection of multiple gene sets was shown by Venny 2.1.0 software (http://bioinfogp.cnb.csic.es/tools/venny/index.html).

2.2. Biological Information Analysis. TargetScan 7.2 (http://www.targetscan.org/vert_72/) and miRWalk (http://mirwalk.umm.uni-heidelberg.de/) were used to predict the target gene(s) of miR-654-5p.

2.3. Cell Culture. The T/G HA-VSMC cell lines were purchased from American Type Culture Collection (ATCC® CRL-1999™, Manassas, USA). The cells were cultured in Roswell Park Memorial Institute (RPMI) medium 1640 containing 10% fetal bovine serum (FBS, Gibco, USA) at 37°C in a 5% CO2 atmosphere. VSMCs were treated with interleukin-1β (IL-1β, 40 ng/mL, MFB18, Sigma-Aldrich, USA), tumor necrosis factor-α (TNF-α, 25 ng/mL, T0157, Sigma-Aldrich, USA), platelet-derived growth factor BB (PDGF-BB, 20 ng/mL, P6101, Sigma-Aldrich, USA), and transforming growth factor-β (TGF-β, 10 ng/mL, T1940, Sigma-Aldrich, USA) for 24 h. After the treatment, CCK-8, wound scratch, Transwell, and qRT-PCR were performed to detect the proliferation, migration, invasion, apoptosis, and miR-654-5p levels, respectively. In addition, VSMCs were treated by different concentrations of PDGF-BB (0 ng/mL, 1 ng/mL, 5 ng/mL, 10 ng/mL, 20 ng/mL, and 40 ng/mL) for 48 h.

2.4. Transfection. Cells were seeded into 6-well plates at 1 × 10^5/mL. The next day, cells were 80-90% confluent and transfected. 20 pmol of scramble, mimics, inhibitor, NC, TCF21, MTAP, and mimics+MTAP (Shanghai Gene Pharmaceutical Co., Ltd., China) were dissolved in 50 μL DMEM (Hyclone, USA) and 1 μL Lipofectamine 2000 (Invitrogen, USA), respectively. Add it to 50 μL DMEM, let stand for 5 min at room temperature, and mix the two. Next, the mixture was added to a 6-well plate and placed in a cell incubator at 37°C with 5% CO2 for continued cultivation. The medium was changed 24 h after transfection, and the cells were harvested after 72 h of culture.

2.5. Construction of miR-654-5p Lentiviral Expression Vector. miR-654-5p primer was designed based on the characteristics of the pLVX-shRNA2 plasmid vector (VT1457, Clontech, USA). miR-654-5p was subjected to PCR amplification, and fragments were separated and purified by 1% agarose gel electrophoresis (T2036, Sigma-Aldrich, USA) for 24 h after PCR amplification, and fragments were separated and purified by 1% agarose gel electrophoresis (T2036, Sigma-Aldrich, USA) and then double-digested by restriction endonucleases BamH I and EcoR I (IVGN0118, Thermo Fisher Scientific, USA) and inserted into a pmirGLO dual-luciferase vector containing the predicted miR-654-5p target gene(s) of miR-654-5p.

2.6. Luciferase Activity Assay. For dual-luciferase reporter assays, 3′ UTR of TCF21 sequence containing miR-654-5p binding sites was inserted into a pmirGLO dual-luciferase vector (Promega, USA) to generate wild-type (WT) pmirGLO:TCF21. The mutant (MUT) of TCF21 sequence in miR-654-5p binding sites was synthesized using a Site-Directed Mutagenesis Kit (F542, Thermo Fisher Scientific, USA) and inserted into a pmirGLO dual-luciferase vector to generate MUT pmirGLO-TCF21. Similarly, 3′ UTR of DDR1 or MTAP containing the predicted miR-654-5p-
binding sites or MUT sites was, respectively, inserted into pmirGLO dual-luciferase vector, named accordingly as pmirGLO-DDR1-3′UTR-WT, pmirGLO-DDR1-3′UTR-MUT, pmirGLO-MTAP-3′UTR-WT, and pmirGLO-MTAP-3′UTR-MUT. After that, the pmirGLO vector containing WT or MT TCF21, DDR1, or MTAP sequence was, respectively, cotransfected with miR-654-5p mimic into T/G HA-VSMC cells by Lipofectamine 2000 (Invitrogen, USA). After incubation for 48 h, the relative luciferase activity in the cells was measured using Dual-Luciferase Reporter Assay protocol (Promega, Madison, WI).

### Table 1: Primers used in real-time PCR analysis.

| Gene    | Primer sequence | Species |
|---------|-----------------|---------|
| miR-1   | Forward: 5′-TAAGTGGGGACAGCAGAAATGC-3′<br>Reverse: 5′-AGCAAGGTAAGAGGAGTAGG-3′ | Human |
| miR-133b| Forward: 5′-CCCCCTTTAACCAGCTAGTG-3′<br>Reverse: 5′-GTGTGGTGAGGAGTCAATT-3′ | Human |
| miR-431 | Forward: 5′-CCGTATCGGTAACGCTG-3′<br>Reverse: 5′-GTATCCAGTTCGGGCTG-3′ | Human |
| miR-654-5p| Forward: 5′-TGGGATGTTAACCCTGTTT-3′<br>Reverse: 5′-GTGTCGTGGAGTCAATT-3′ | Human |
| miR-376c| Forward: 5′-TGGTATCCAGTGCGT-3′<br>Reverse: 5′-GTGTCGTGGAGTCAATT-3′ | Human |
| miR-136 | Forward: 5′-ACGGTCGTATCCAGTCAAT-3′<br>Reverse: 5′-GTATCCAGTGCGTGG-3′ | Human |
| miR-411 | Forward: 5′-TTGCGGTGCAATCTC-3′<br>Reverse: 5′-GTGTCGTGGAGTCAATT-3′ | Human |
| miR-299-3p| Forward: 5′-TGGGATGTTAACCCTGTTT-3′<br>Reverse: 5′-GTGTCGTGGAGTCAATT-3′ | Human |
| miR-337-5p| Forward: 5′-ACGGTCGTATCCAGTCAAT-3′<br>Reverse: 5′-GTATCCAGTGCGTGG-3′ | Human |
| miR-323-3p| Forward: 5′-TGGGATGTTAACCCTGTTT-3′<br>Reverse: 5′-GTGTCGTGGAGTCAATT-3′ | Human |
| miR-539 | Forward: 5′-CCGGTATCCAGTGCGT-3′<br>Reverse: 5′-GTGTCGTGGAGTCAATT-3′ | Human |
| miR-376a| Forward: 5′-TGGGATGTTAACCCTGTTT-3′<br>Reverse: 5′-GTGTCGTGGAGTCAATT-3′ | Human |
| miR-410 | Forward: 5′-TTGTCGTGCAATCTC-3′<br>Reverse: 5′-GTGTCGTGGAGTCAATT-3′ | Human |
| miR-329 | Forward: 5′-TGGGATGTTAACCCTGTTT-3′<br>Reverse: 5′-GTGTCGTGGAGTCAATT-3′ | Human |
| TCF21   | Forward: 5′-TCCTGTGCTTCTCTG-3′<br>Reverse: 5′-TTTCCCCACACATCAAGG-3′ | Human |
| MTAP    | Forward: 5′-GGCTGAGGTCGGGT-3′<br>Reverse: 5′-GGACTGAAGGTCTCATAGTGGT-3′ | Human |
| GAPDH   | Forward: 5′-CATTAAGTTGTCATGAC-3′<br>Reverse: 5′-ATTATGAACCGCTTCGCAA-3′ | Human |
| U6      | Forward: 5′-AUAACCGCTTCGCAA-3′<br>Reverse: 5′-AUAACCGCTTCGCAA-3′ | Human |

2.7. Construction of Ultrasound Microbubbles and Transfection of Smooth Muscle Cells. SonoVue ultrasound microbubble contrast agent (Bracco, USA) was dissolved in 5 mL physiological saline to form a microbubble suspension. T/G HA-VSMC cells in logarithmic growth phase were selected and divided into blank group (cells without any
Cell suspension was seeded in a 6-well culture plate, and then, microbubble contrast agent was immediately added into cell suspension seeded in a 6-well culture plate, and the suspension was then irradiated by a UVX radiometer. Microbubble ultrasound group immediately added to the cell suspension seeded in a 6-well culture plate, and the suspension was irradiated by a UVX radiometer (UV Products, Upland, CA), microbubble ultrasound group immediately added into cell suspension seeded in a 6-well culture plate, and then, the suspension was irradiated by a UVX radiometer.

**Table 2: Differentially expressed miRNAs in platelets between patients with premature coronary artery disease and healthy controls.**

| ID     | P value | t   | B   | logFC |
|--------|---------|-----|-----|-------|
| hsa-miR-1 | 0.03     | -2.28 | -3.64 | -0.49 |
| hsa-miR-133b | 0.04     | -2.05 | -4.10 | -0.45 |
| hsa-miR-431 | 0.01     | -2.78 | -2.54 | -0.37 |
| hsa-miR-654-5p | 0.01    | -2.65 | -2.84 | -0.36 |
| hsa-miR-376c | 0.02     | -2.49 | -3.21 | -0.35 |
| hsa-miR-136 | 0.03     | -2.19 | -3.82 | -0.33 |
| hsa-miR-411 | 0.01     | -2.56 | -3.05 | -0.33 |
| hsa-miR-299-3p | 0.01    | -2.74 | -2.64 | -0.32 |
| hsa-miR-337-5p | 0.02     | -2.41 | -3.38 | -0.31 |
| hsa-miR-323-3p | 0.04     | -2.07 | -4.06 | -0.30 |
| hsa-miR-539 | 0.01     | -2.55 | -3.07 | -0.30 |
| hsa-miR-376a | 0.04     | -2.07 | -4.05 | -0.27 |
| hsa-miR-410 | 0.06     | -1.93 | -4.31 | -0.25 |
| hsa-miR-329 | 0.05     | -2.02 | -4.14 | -0.25 |

2.8. **Cell Viability.** Cells at logarithmic growth phase were selected, and the cell density was adjusted to $1 \times 10^5$ mL in Dulbecco’s modified Eagle’s medium (DMEM; C11995500BT, Gibco, MA, USA) medium containing 10% FBS. Next, the cells were inoculated into a 96-well plate, and 10 μL cell counting kit-8 (CCK-8, Sigma-Aldrich, USA) solution was added into each well and incubated for 4 h. Absorbance at 450 nm was determined by enzyme microscopy (Multiskan GO, Shanghai Bajiu Industrial Co., Ltd., Shanghai, China).

2.9. **Cell Apoptosis.** Cells at logarithmic growth phase were selected, the cell density was adjusted to $1 \times 10^5$ mL, and the cells were then washed for four times by PBS and digested by trypsin for 2 min. Next, trypsin was discarded, and 1 mL RPMI-1640 was added into cells, which were repeatedly blown into a single cell fluid. All cell suspensions were transferred into 15 mL centrifugal tube and centrifuged at 1000 × g for 5 min at 4°C. Subsequently, the supernatant was discarded and 1 mL RPMI-1640 was added into the centrifugal tube. The cells were resuspended in 1× Annexin binding buffer, 5 μL fluorescein isothiocyanate (FITC) Annexin V, and 1 μL of 100 μg/mL propidium iodide (PI) (85-BMS500PI, MULTI SCIENCES, Hangzhou, China) solution, and the 300 μL 1× Annexin binding buffer was added into the cell suspension at room temperature and held for 15 min. Finally, the stained cells were analyzed by flow cytometry.

2.10. **Wound Scratch.** Transfected cells were seeded into 6-well plates at $5 \times 10^5$ per well. After 24 hours, scratch the cells quickly with a uniform width. After washing the suspension cells, culture the cells with a low serum concentration (1%) medium. Then, the 0 h and 48 h time points were selected to record the cell migration at the same location by photographing, and the migration distance was measured by ImageJ software version 1.8.0. Relative mobility = ($0 \text{ h scratch width} - 48 \text{ h scratch width})/0 \text{ h scratch width} × 100%.

2.11. **Transwell.** After transfection for 24 h, the transfected cells were diluted into a density of $1 \times 10^5$/mL and pipetted into the upper chamber of the Transwell containing suspension solution with 0.2 mL FBS-free DMEM, while the complete medium was added into the lower chamber. After incubation for 48 h, the upper side of the polycarbonate membrane was wiped, leaving the underside of the membrane containing invaded cells. Finally, the cells were stained by crystal violet for 15 min at normal atmospheric temperature. Three random areas on each membrane were selected to count the number of the migrated cells under a microscope ($\times$200). ImageJ software (version 1.8.0) was used to analyze the images in this essay.

2.12. **Colony Formation Assay.** The cells were transfected and digested, counted, and cultured in 12-well plates at 100 cells per well at 37°C in a 5% CO₂ atmosphere for 3 weeks, and the conditioned medium was changed every 3 d to observe the formation of clones. The culture was terminated when the number of cloned cells was within 50-150.
Figure 2: Effects of growth factors on the growth of VSMCs and miRNA expression. (a) CCK-8 was performed to detect viability of human aortic smooth muscle cell treated by IL-1β (40 ng/mL), TNF-α (25 ng/mL), PDGF-BB (20 ng/mL), and TGF-β (10 ng/mL) for 24 h at 37°C in a 5% CO₂ atmosphere (n = 3, *P < 0.05, **P < 0.01, and ***P < 0.001 vs. control). (b, d) The migration distance of human aortic smooth muscle cell was detected by wound scratch assay (n = 3, *P < 0.05, **P < 0.01, and ***P < 0.001 vs. control). (c, e) The invasion of human aortic smooth muscle cell was detected by Transwell. (f) qRT-PCR was performed to detect the expression of miRNA in human aortic smooth muscle cell treated by IL-1β, TNF-α, PDGF-BB, and TGF-β for 24 h at 37°C in a 5% CO₂ atmosphere (n = 3, *P < 0.05, **P < 0.01, and ***P < 0.001 vs. control). (g) The effect of different treatment times of PDGF-BB (20 ng/mL) on the expression of miR-654-5p in VSMCs by qRT-PCR. (h) The effect of different treatment concentrations of PDGF-BB (1 ng/mL, 5 ng/mL, 10 ng/mL, 20 ng/mL, and 40 ng/mL) on the expression of miR-654-5p in VSMCs by qRT-PCR. (i) CCK-8 was performed to detect the viability of VSMCs treated by different treatment concentrations of PDGF-BB (1 ng/mL, 5 ng/mL, 10 ng/mL, 20 ng/mL, and 40 ng/mL).
fields, the medium was discarded, and the cells were rinsed twice in Dulbecco's Phosphate-Buffered Saline (DPBS, D8662, Sigma-Aldrich, USA). 1 mL methanol (34860, Sigma-Aldrich, USA) was added into each well, and the cells were fixed for 15 min. 1 mL Giemsa (999D715, Thermo Fisher Scientific, USA) was added into each well for 30 min. Colony formation rate was calculated by colony formation rate = (number of colonies/number of seeded cells) × 100%. Each treatment was carried out in triplicate.

2.13. Immunofluorescence. The cells were inoculated in the petri dish at the cell density of $1 \times 10^5$/mL for cell crawling, and the cells were divided into scramble-transfected cells, mimic-transfected cells, and scramble-transfected cells treated with 20 ng/mL PDGF and mimic-transfected cells treated with 20 ng/mL PDGF. After the treatment, the cells were centrifuged at $1000 \times g$ at 4°C for 5 min, and immunofluorescence was performed for identifying the fluorescent of the cells. Briefly, the cell smear was washed by PBS for three times and then fixed on ice acetone (01000356-25g, Beijing Ouhe Technology Co., Ltd., http://www.ouhechem.com/, China) for 15 min. Next, while the cell smear was dried, PBS was used to wash the cells for three times. TCF21/Pod1 antibody (C07617Cy3, Signalway Antibody, USA)

---

**Figure 3: Expression of miR-654-5p in PDGF-treated VSMCs.**

(a) qRT-PCR was performed to detect the miR-654-5p mRNA expression in VSMCs transfected with miR-654-5p mimics. (b) qRT-PCR was performed to detect the expression of miR-654-5p in miR-654-5p mimic-transfected VSMCs treated by PDGF for 24 h. (c) The viability of miR-654-5p mimic-transfected VSMCs treated by PDGF was detected by CCK-8. (d) Wound scratch was performed to detect the migration of miR-654-5p mimic-transfected VSMCs treated by PDGF. (e) Transwell was performed to detect the invasion of miR-654-5p mimic-transfected VSMCs treated by PDGF.
and MTAP antibody (ab23393, 1:100, Abcam, USA) were added into the cells, respectively, and incubated together at 4°C in a heat preservation box incubation. Next, conjugated secondary antibody was added into the cells at 37°C for 2 h, and the cells were washed by PBS for three times and then incubated with DAPI for 3 min. Finally, fluorescence of the cells was determined under a fluorescence microscope (Delta Optical IB-100, Delta Optical, Poland).

2.14. Source and Grouping of Rats. The animal model was established using 8-week-old male Sprague-Dawley rats \((n=66)\). Animal experiments were approved by Nanjing Medical University. Rats were randomly divided into control group \((n=6,\) rats were routinely fed\), sham-operated control group \((n=6,\) sham-operated\), control group \((n=6,\) sham-operated rats were injected with miR-654-5p cocultured plasmid in the tail vein\), liposome group \((n=6,\) cocultured liposomes carrying miR-654-5p plasmid were injected into the tail vein of rats\), vascular injury model SonoVue group \((n=6,\) microbubble contrast agent and plasmid were injected into rat vascular injury model via tail vein\) (UVX radiometer (UV Products, Upland, CA) irradiation), microbubble group \((n=6,\) microbubble injury model\) (bubble

![Figure 4: The effects of miR-654-5p on cell viability, migration, and invasion. (a) qRT-PCR was performed to detect the miR-654-5p mRNA expression in VSMCs transfected with miR-654-5p inhibitor. (b) qRT-PCR was performed to detect the expression of miR-654-5p in miR-654-5p inhibitor-transfected VSMCs treated by PDGF for 24h. (c) The viability of miR-654-5p inhibitor-transfected VSMCs treated by PDGF was detected by CCK-8. (d) Wound scratch was performed to detect the migration of miR-654-5p inhibitor-transfected VSMCs treated by PDGF. (e) Transwell was performed to detect the invasion of miR-654-5p inhibitor-transfected VSMCs treated by PDGF.](image-url)
Figure 5: Continued.
contrast agent and plasmid were injected into rat vascular injury model via tail vein), ultrasound group \((n = 6, \text{ plasmid was injected into rat vascular injury model through tail vein and then irradiated with UVX radiometer})\), and microbubble ultrasound \((n = 6, \text{ microbubble contrast agent was injected into the tail vein of a rat model of vascular injury and irradiated with a UVX radiometer})\).

2.15. Establishment of Rat Vascular Injury Model. Each rat was intraperitoneally injected with 30-40 mg/kg pentobarbital hydrochloride \((69020181, \text{ Sinopharm Chemical Reagent Beijing Co., Ltd. (http://www.crc-bj.com/Products.aspx?/)))\), China). The rat was successfully anesthetized, and an incision of about 3 cm was made in the middle of the rat’s neck. The left common carotid artery is found next to the left trachea, dividing the vagus and sympathetic nerves around the artery. A small opening was made at the distal end of the vessel, and a 2.0 Fogarty catheter microembolization ball \((\text{Edwards Lifesciences, Irvine, California})\) was injected into the vessel along the incision. When the rats could breathe stably, endotracheal intubation was removed, and 1000,000 units of penicillin sodium \((\text{SP303201, Sinopharm Chemical Reagent Beijing Co., Ltd., (http://www.crc-bj.com/Products.aspx?q=%e7%94%b2%e9%86%9b&&p=1/), China})\), dehydrated by gradient alcohol \((80\%, 90\%, 95\%, 100\%)\), made transparent by xylene \((10023418, \text{ Sinopharm Chemical Reagent Beijing Co. Ltd., http://www.crc-bj.com/default.aspx, China})\), immersed and embedded in wax, and finally made into tissue slices \((4 \mu m)\). Slides containing tissue were deparaffinized in xylene, dephenylated with 100%, 95%, 80%, and 70% ethanol for 2 min, and then rinsed twice with distilled water to rehydrate. The slides were stained by hematoxylin for 20 min and then washed under running water to remove the blue. The slides were placed in acidification solution \((\text{hydrochloric acid (10011008, Sinopharm Chemical Reagent Beijing Co., Ltd., (http://www.crc-bj.com/default.aspx, China)) : 75\% ethanol = 1 : 99})\) for 1 min to remove cytoplasm blue. The slides were washed under tap water for 10 min, then stained by eosin \((\text{Beijing Zhongshan Jingqiao Biotechnology Co., Ltd., http://med9519.yixie8.com/, China})\) for 15 min, and then dehydrated in 100% ethanol for 15 min. Xylene was made transparent in 15 min; finally, neutral gum was used to seal the film, and an optical microscope \((\text{CKX31, Olympus, Japan})\) was used to observe the pathological changes of rat aortic tissues.

2.16. Hematoxylin and Eosin (HE) Staining. The sections with rat aortic tissue were stained by HE staining. The tissues were fixed by formaldehyde \((\text{SF877503, Sinopharm Chemical Reagent Beijing Co., Ltd., (http://www.crc-bj.com/Products.aspx?q=%e7%94%b2%e9%86%9b&&p=1/), China})\), dehydrated by gradient alcohol \((80\%, 90\%, 95\%, 100\%)\), made transparent by xylene \((10023418, \text{ Sinopharm Chemical Reagent Beijing Co., Ltd., (http://www.crc-bj.com/Products.aspx?q=%e7%94%b2%e9%86%9b&&p=1/), China})\), dehydrated by gradient alcohol \((80\%, 90\%, 95\%, 100\%)\), made transparent by xylene, dephenylated with 100%, 95%, 80%, and 70% ethanol for 2 min, and then rinsed twice with distilled water to rehydrate. The slides were stained by hematoxylin for 20 min and then washed under running water to remove the blue. The slides were placed in acidification solution \((\text{hydrochloric acid (10011008, Sinopharm Chemical Reagent Beijing Co., Ltd., (http://www.crc-bj.com/default.aspx, China)) : 75\% ethanol = 1 : 99})\) for 1 min to remove cytoplasm blue. The slides were washed under tap water for 10 min, then stained by eosin \((\text{Beijing Zhongshan Jingqiao Biotechnology Co., Ltd., http://med9519.yixie8.com/, China})\) for 15 min, and then dehydrated in 100% ethanol for 15 min. Xylene was made transparent in 15 min; finally, neutral gum was used to seal the film, and an optical microscope \((\text{CKX31, Olympus, Japan})\) was used to observe the pathological changes of rat aortic tissues.

2.17. Immunohistochemical Staining (IHC). After dewaxing and hydrating rat aortic tissue sections, the sections were soaked in citrate buffer \((\text{pH } 6.0)\) and heated in a microwave oven for 10 minutes for antigen retrieval. After rinsing with distilled water for 2 min, the sections were soaked in 3% \(\text{H}_2\text{O}_2\) for 10 min at room temperature to eliminate endogenous peroxidase activity. Anti-TCF21 antibody \((\text{ab32981, 1 : 100, Abcam, USA})\) and anti-MTAP antibody \((\text{ab126770, 1 : 100, Abcam, USA})\) were added to the sections and incubated overnight at 4°C. Sections were then incubated with goat anti-rabbit IgG H&L (HRP) \((1 : 1000; \text{ab205718, Abcam, USA})\) for 30 minutes at 37°C. Sections were stained...
with DAB Horseradish Peroxidase Chromogenic Kit (Beyotime, Shanghai, China) and observed under a light microscope (CKX31, Olympus, Japan).

2.18. Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR). Total RNAs in cells and tissues were extracted using Trizol reagent (15596018, Thermo Fisher Scientific, USA), and NanoDrop (FSC-6539918, (http://eGeneralMedical.com/), USA) was used to determine RNA concentration and purity. Total RNA (1 μg) was converted into cDNA using a SuperScript II first-strand cDNA synthesis system (Invitrogen, USA). The mRNA expression levels were determined by SYBR-Green PCR Master Mix (Thermo Fisher Scientific, USA) in the 7500 Real-Time PCR System (Thermo Fisher Scientific, USA). The PCR program was set as follows: pretreatment at 95°C for 30 s, at 60°C for 30 s, at 60°C for 30 s for 45 cycles. The 2^ΔΔCT method was used to determine the expression levels of RT-PCR products [16]. Primers are summarized in Table 1.

2.19. Western Blot. The total protein of cells and tissues was extracted using RIPA Lysis and Extraction Buffer (89901, Scramble TCF21 (17 KD) (42 KD) β-Actin

**Figure 6:** Effects of miR-654-5p on TCF21 expression in VSMCs. (a, b) Western blotting was performed to determine the expression level of TCF21 in miR-654-5p mimic-transfected VSMCs treated by PDGF. (c) qRT-PCR was used to detect the TCF21 mRNA expression level in miR-654-5p mimic-transfected VSMCs treated by PDGF. (d, e) Western blotting was used to determine the expression level of TCF21 in miR-654-5p inhibitor-transfected VSMCs treated by PDGF. (f) qRT-PCR was used to detect the TCF21 mRNA expression level in miR-654-5p inhibitor-transfected VSMCs treated by PDGF.
Thermo Fisher Scientific, USA). Extracted protein mixture was centrifuged at 1000 × g for 5 min at 4°C. BCA protein kit (QPBCA, Sigma-Aldrich, USA) was used to determine the protein concentration. The proteins were separated by SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) membranes (EMD Millipore, USA). The membrane was blocked by 5% nonfat milk at room temperature for 1 h. The membrane was incubated with anti-TCF21 antibody (ab32981, 1:100, Abcam, USA), anti-MTAP antibody (ab126770, 1:100, Abcam, USA), and β-actin (mouse, 1:1000, ab8226, Abcam) at 4°C overnight. After washing, the membrane was incubated with goat anti-mouse or goat anti-rabbit IgG (H+L) (Proteintech, USA) for 2 h and then washed by PBST for three times. The bands were detected by using an ECL kit (MAB5350, Sigma-Aldrich, USA) and scanned by a supersensitive multifunctional imager (ImageJ, version 4.7, AMERSHAM IMAGER 600, GE).

2.20. Statistical Analysis. The statistical analysis was performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). The results were expressed as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) was used for analyzing the differences between multiple groups, and t-test was used for comparing the differences in the mean between the continuous variables. The

![Figure 7: Immunofluorescence detects TCF21 expression. (a) Immunofluorescence detection of TCF21 in miR-654-5p mimic-transfected VSMCs treated by PDGF. (b) Immunofluorescence detection of TCF21 in miR-654-5p inhibitor-transfected VSMCs treated by PDGF.](image-url)
experiment was conducted in triplicate. $P$ less than 0.05 was considered as statistically significant.

3. Results

3.1. Differentially Expressed Genes for Early-Onset Coronary Heart Disease. Bioinformatics analysis was conducted to obtain miRNAs with different platelet expressions in patients with early coronary heart disease and healthy controls. According to Figure 1, bioinformatics analysis identified 14 miRNAs differentially expressed in platelets in patients with early-onset coronary heart disease and healthy controls (group 1), and a total of 155 miRNAs were differentially expressed in platelets of healthy controls after the drug administration (group 2). Through R software, 5 differentially expressed genes, which were obtained through Venny analysis, may be confounding factors; thus, the 5 genes were removed, leaving miR-1, miR-133b, miR-431, miR-654-5p, miR-376c, miR-136, miR-411, miR-299-3p, miR-337-5p, miR-323-3p, miR-539, miR-376a, miR-410, and miR-329 (Table 2).
3.2. Effects of Growth Factors on the Growth of VSMCs and miRNA Expression. IL-1β, TNF-α, platelet-derived growth factor BB (PDGF-BB), and transforming growth factor-β (TGF-β) were used to stimulate VSMCs and expressions of genes related to VSMC proliferation, migration, invasion, and apoptosis. As shown in Figure 2, the result showed that the viability of VSMCs stimulated by growth factors increased compared to the control group (P < 0.5 and P < 0.01, Figure 2(a)); moreover, the migration distance (Figures 2(b) and 2(d)) and invasion (Figures 2(c) and 2(e)) of the cells increased significantly (P < 0.5, P < 0.01). QRT-PCR was performed to detect the expression of miRNA (Figure 2(f)), and the results showed that the expression of miR-654-5p was significantly downregulated in cells of each treatment group (IL-1β-treated group, TNF-α-treated group, PDGF-BB-treated group, and TGF-β-treated group). Since the expression of miR-654-5p was significantly decreased after PDGF-BB treatment, the cells were treated by PDGF-BB to explore the effects of PDGF-BB (20 ng/mL) for different treatment times (0, 3 h, 6 h, 12 h, 24 h, and 48 h) on miRNA expressions in VSMCs, and the results showed that the expression of miR-654-5p decreased in the cells treated by PDGF-BB for 3 h, 6 h, 12 h, 24 h, and 48 h (P < 0.01, Figure 2(g)). In addition, the miR-654-5p expression decreased in VSMCs treated by different concentrations (0, 1, 5, 10, 20, and 40 ng/mL) of PDGF-BB (P < 0.05 and P < 0.01, Figure 2(h)), indicating that the viability of VSMCs treated by different concentrations of PDGF-BB increased in a dose-dependent manner (P < 0.05 and P < 0.01, Figure 2(i)).
Figure 10: Continued.
3.3. Expression of miR-654-5p in PDGF-Treated VSMCs and the Effects of miR-654-5p on Cell Viability, Migration, and Invasion. miR-654-5p mimics were transfected into VSMCs, and we found that the expression level of miR-654-5p was increased significantly in the cells (P < 0.01, Figure 3(a)), whereas the expression of miR-654-5p was significantly inhibited when the cells were transfected with mimics treated by PDGF (P < 0.01, Figure 3(b)). Moreover, the viability decreased in VSMCs transfected with miR-654-5p mimics but increased in miR-654-5p mimic-transfected VSMCs treated by PDGF (P < 0.05 and P < 0.01, Figure 3(c)). Wound scratch was performed to determine the effect of overexpressed miR-654-5p on the migration of PDGF-treated cells, and the result showed that overexpression of miR-654-5p could decrease the migration of VSMCs; however, when the cells were treated by PDGF, the migration of the cells was significantly promoted (P < 0.05 and P < 0.01, Figure 3(d)). Transwell was performed to detect the effect of overexpression of miR-654-5p on migration of PDGF-treated cells, and we found that overexpression of miR-654-5p inhibited the invasion of VSMCs, while cell invasion was significantly promoted when the cells were treated by PDGF (P < 0.05 and P < 0.01, Figure 3(e)). Moreover, inhibitor was transfected into the cell to investigate the effects of low expression of miR-654-5p on cell viability, migration, and invasion. Firstly, we confirmed that the expression of miR-654-5p was inhibited in inhibitor-transfected VSMCs (P < 0.01, Figure 4(a)), and the expression level was significantly inhibited when the inhibitor-transfected cells were treated by PDGF (P < 0.05 and P < 0.01, Figure 4(b)). Next, the results of CCK-8 showed that the viability was increased in VSMCs transfected by inhibitor as compared with scramble-transfected cells, and it was significantly increased in inhibitor-transfected VSMCs treated by PDGF (P < 0.05 and P < 0.01, Figure 4(c)). Wound scratch data demonstrated that low-expressed miR-654-5p increased the migrations of VSMCs and inhibitor-transfected VSMCs treated by PDGF as compared with the inhibitor-transfected VSMCs (P < 0.05 and P < 0.01, Figure 4(d)). Transwell results indicated that low-expressed miR-654-5p promoted the invasions of VSMCs and inhibitor-transfected VSMCs treated by PDGF as compared with the inhibitor-transfected VSMCs (P < 0.05 and P < 0.01, Figure 4(e)).

3.4. Target Gene Prediction of miR-654-5p and Its Effect on Target Gene Expression in VSMCs. We used TargetScan and miRWalk to predict 42 genes that have a targeting relationship with miR-654-5p (Figure 5(a)); in addition, previous studies have shown that TCF21, DDR1, and MTAP are associated with coronary heart disease and blood vessels and vascular smooth muscle damage [17–19]. TargetScan 7.2 predictions revealed that miR-654-5p has reciprocal binding sites with TCF21, DDR1, and MTAP (Figure 5(b)). In addition, we constructed pmirGLO dual-luciferase reporter vectors, namely, TCF21-WT and TCF21-MUT, and cotransfected pmirGLO-TCF21 with miR-654-5p mimics into VSMCs and found that TCF21-WT luciferase vitality significantly improved inhibition (P < 0.01, Figure 5(c)). DDR1-WT and DDR1-MUT were constructed and cotransfected with miR-654-5p mimic into VSMCs; the luciferase activity of DDR1-WT (P < 0.05, Figure 5(d)) and MTAP-WT was significantly inhibited (P < 0.01, Figure 5(e)). The significant decrease in luciferase activity following TCF21 and MTAP binding to the mimic indicated that miR-654-5p binds more strongly to TCF21 and MTAP in cells. Therefore, we further explored the effect of different expression of miR-654-5p on TCF21 and MTAP, and the results of western blot (Figures 6(a) and 6(b)) and qRT-PCR (Figure 6(c)) showed that miR-654-5p mimics significantly inhibited. The expression of TCF21 was increased in VSMCs, whereas it was increased in miR-654-5p mimic-PDGF-treated transfected cells (P < 0.01). However, PDGF significantly promoted the expression level of TCF21 in VSMCs transfected with miR-654-5p inhibitor (P < 0.05 and P < 0.01, Figures 6(d)–6(f)). Furthermore, immunofluorescence staining with TCF21 antibody showed that the fluorescence of TCF21 was significantly increased in PDGF-
Figure 11: Continued.
the expression of MTAP was significantly increased in PDGF treatment (Figure 7(b)).

In addition, the results of western blotting (Figures 8(a) and 8(b)) and qRT-PCR (Figure 8(c)) demonstrated that the expression of MTAP was significantly inhibited by miR-654-5p mimics in VSMCs, but was elevated in miR-654-5p mimic-transfected cells treated by PDGF (P < 0.01). However, PDGF greatly upregulated the expression level of MTAP in VSMCs transfected with miR-654-5p inhibitor (P < 0.05 and P < 0.01, Figures 8(d)-8(f)). Furthermore, immunofluorescence staining on MTAP antibody showed that the fluorescence MTAP increased significantly in VSMCs treated by PDGF, but was inhibited in PDGF-treated VSMCs transfected with mimics (Figure 9(a)). However, the fluorescence amount of MTAP was significantly increased in PDGF-treated VSMCs transfected with inhibitor (Figure 9(b)).

### Figure 11: Effects of miR-654-5p on VSMC viability, migration, and invasion by targeting MTAP. (a) The expression of MTAP in MTAP-transfected VSMCs was detected by qRT-PCR. (b) The expression of miR-654-5p in mimic- or MTAP-transfected VSMCs was detected by qRT-PCR. (c) The expression of MTAP in mimic- or MTAP-transfected VSMCs was detected by qRT-PCR. (d) Western blotting was used to determine the expression level of MTAP in mimic- or MTAP-transfected VSMCs. (e) The viability of mimic- or MTAP-transfected VSMCs was detected by CCK-8. (f) Wound scratch was used to detect the migration of mimic- or MTAP-transfected VSMCs. (g) Transwell was used to detect the invasions of mimic- or MTAP-transfected VSMCs. (h) Cloning formation experiment was used to detect the proliferation of mimic- or MTAP-transfected VSMCs. (i) Relative colony numbers. (h)

3.6. Effects of miR-654-5p on VSMC Viability, Migration, and Invasion through Targeting MTAP. MTAP overexpression vector and mimics were transfected into the cells to further investigate the effect of miR-654-5p on cell viability, migration, and invasion through targeting MTAP. We observed that the expression of MTAP was significantly increased in VSMCs transfected with MTAP overexpression vector (P < 0.01, Figure 11(a)); however, when the cells transfected were with MTAP overexpression vector, the expression of miR-654-5p was significantly inhibited (P < 0.01, Figure 11(b)), and overexpressed miR-654-5p could inhibit the MTAP expression (P < 0.01, Figures 11(c) and 11(d)).

The viability was inhibited in VSMCs transfected with mimics, whereas overexpression of MTAP reversed the effect of mimics on cell viability (P < 0.05 and P < 0.01, Figure 11(e)). Wound scratch showed that the migration of VSMCs was significantly increased in the cells transfected with MTAP, but mimics inhibited the effect of MTAP overexpression vector on migration of VSMCs (P < 0.01 and P < 0.05, Figure 11(f)). Wound scratch data showed that the invasion of VSMCs was significantly increased in the cells transfected with MTAP, but mimics inhibited the effect of MTAP overexpression vector on proliferation of VSMCs (P < 0.01, Figure 11(h)).
Figure 12: Transfection efficiency of miR-654-5p and effects of ultrasound-mediated SonoVue-miR-654-5p microbubble on VSMC viability, migration, and invasion. (a) The expression of miR-654-5p in VSMCs transfected with SonoVue-microRNA and adenovirus was detected by qRT-PCR. (b) The viability of VSMCs transfected with SonoVue-microRNA and adenovirus was detected by CCK-8. (c, f) Wound scratch detection of the effect of SonoVue-microRNA overexpression on VSMC migration. (d, g) Transwell was used to detect the invasion of VSMCs with overexpressed SonoVue-microRNA. (e, h) Cloning formation experiment was used to detect the proliferation of VSMCs with overexpressed SonoVue. Abbreviations: qRT-PCR: quantitative real-time polymerase chain reaction.
3.7. Transfection Efficiency of miR-654-5p and TCF21 and Effects of Ultrasound-Mediated SonoVue-miR-654-5p Microbubble on VSMC Viability, Migration, Invasion, and Apoptosis. miR-654-5p expression in cells was significantly promoted by SonoVue-miR-654-5p overexpression ($P < 0.01$, Figure 12(a)). The viability was significantly inhibited by SonoVue-miR-654-5p overexpression liposome transfected into VSMCs ($P < 0.01$, Figure 12(b)). SonoVue-miR-654-5p overexpression inhibited the migration of VSMCs ($P < 0.01$, Figures 12(c) and 12(f)), and cell invasion was inhibited in VSMCs transfected with SonoVue-miR-654-5p overexpression liposome ($P < 0.01$, Figures 12(d) and 12(g)). Moreover, colony formation assay showed that the proliferation of VSMCs decreased significantly in the cells transfected with SonoVue-miR-654-5p overexpression liposome ($P < 0.01$, Figures 12(e) and 12(h)). In addition, apoptosis of VSMCs was significantly promoted when SonoVue-miR-654-5p overexpression liposome was transfected into the cells ($P < 0.01$, Figures 13(a) and 13(b)). The results of qRT-PCR (Figure 13(c)) and western blotting (Figure 13(d)) showed that the TCF21 expression was significantly inhibited in VSMCs transfected with SonoVue-miR-654-5p overexpression liposome ($P < 0.01$).

3.8. Effects of Ultrasound-Mediated SonoVue-miR-654-5p Microbubble Contrast Agent on Vascular Injury Model. Injury in rat carotid artery was created by 2.0 Fogarty catheter balloon to establish carotid artery injury model as a positive group. After the establishment of the rat vascular injury model, pathological examination showed a significant increase in the degree of stenosis of the vascular vessels in the model group as compared with the control group and the sham group (Figure 14(a)); meanwhile, in rat vascular injury model, blood flow velocity increased significantly ($P < 0.01$, Figure 14(b)), and vascular diameter decreased significantly greatly ($P < 0.01$, Figure 14(c)). The result of
qRT-PCR showed that the miR-654-5p expression level was significantly downregulated in the model group \((P < 0.01, \text{ Figure 14(d)})\), and from Figures 14(e) and 14(f), it was found that TCF21 expression increased noticeably in the model group \((P < 0.01)\). Moreover, histopathologic staining showed that the degree of vascular stenosis was highly obvious in the model group (Figure 14(g)). Furthermore, ultrasound-mediated SonoVue-miR-654-5p microbubble was used to treat the rat model of vascular injury, and the results showed that the degree of vascular stenosis was significantly improved in the model treated by SonoVue-miR-654-5p (Figure 15(a)), and in the rat vascular injury model, blood flow velocity decreased \((P < 0.05, \text{ Figure 15(b)})\), and vascular diameter increased as compared with untreated rats.
Figure 15: Effects of ultrasound-mediated SonoVue-miR-654-5p microbubble contrast agent on vascular injury model. (a) SonoVue delivers microRNA into the vascular wall, and the pathological degree of vascular stenosis in the model was examined. (b) Blood flow velocity in rat vascular injury model was measured by intelligent analysis. (c) Vascular diameter in rat vascular injury model was measured by straightedge. (d) qRT-PCR was used to detect the expression of miR-654-5p in rat vascular injury model treated by SonoVue-microRNA. (e) Western blotting was used to determine the expression level of TCF21 in a rat vascular injury model treated by SonoVue-microRNA. (f) Immunohistochemical assay was used to observe the damage of tissue of rat vascular injury model treated by SonoVue-microRNA.
(P < 0.05, Figure 15(c)). The result of qRT-PCR showed that
the miR-654-5p expression level was significantly upregulated
in the model group treated by SonoVue-miR-654-5p
(P < 0.01, Figure 15(d)); moreover, from Figures 15(e) and
15(f), it could be found that the TCF21 expression decreased
significantly in the model group treated by SonoVue-miR-
654-5p (P < 0.01). Histopathologic staining showed that vas-
cular stenosis was inhibited in the model group treated by
SonoVue-miR-654-5p (Figure 15(g)).

4. Discussion
Phenotypic transformation of VSMCs is an important cause
of vascular stenosis [9]. At present, there are mainly several
molecular biological mechanisms involved in the phenotypic
transformation of VSMCs. Inhibition of miR-145 expression
leads to airway smooth muscle cell proliferation and migra-
tion and downregulates the expression of airway type I col-
lagen and contractile protein MHC in smooth muscle cells
[20]; moreover, Wang showed that miRNA-195 can reduce
proliferation and migration of VSMCs and inhibit the syn-
thesis of IL-1β and IL-6 in VSMCs [21]. In this study,
through bioinformatics analysis, we found that miR-654-5p
is a differentially expressed gene in patients with coronary
heart disease and healthy subjects. The current study
explored the effects of miR-654-5p on phenotypic transforma-
tion of VSMCs, as there is currently a lack of research
on such an aspect. We found that inflammatory factors play
a key role in the phenotypic transformation of VSMCs;
moreover, a study found that IL-1β can stimulate the prolif-
eration and migration of VSMCs through P2Y2 receptor
[22] and that inhibiting TNF-α, TGF-β, and PDGF-BB pro-
duction could inhibit proliferation and invasion of VSMCs
[23, 24]. In the study, VSMCs was stimulated by IL-1β,
TNF-α, TGF-β, and PDGF-BB, and the results showed that
the viability, migration, and invasion of VSMCs were pro-
moted, which was consistent with previous studies [23, 24].
The study found that miR-638 was highly expressed in
human VSMCs. When PDGF-BB was used to treat the cells,
the expression of miR-638 was downregulated in dose- and
time-dependent manners [25]. Subsequently, we observed
that the expression of miR-654-5p decreased by PDGF-BB treat-
ment in dose- and time-dependent manners, while
overexpression of miR-654-5p inhibited the proliferation,
invasion, and migration of smooth muscle cells by PDGF-
BB. At the same time, inhibition of miR-654-5p enhanced the
effect of PDGF-BB on the cells.

Previous study confirmed that miR-328 inhibited PDGF-
BB-induced pulmonary artery smooth muscle cell prolifera-
tion and migration by binding to PIM-1 [26]. miR-638
inhibits the proliferation and migration of smooth muscle
cell induced by PDGF-BB through Nor1 [25]. It was also
reported that miR-654-5p can bind to genes to regulate the
proliferation and metastasis of various tumors [27, 28].
In this study, we further investigated the effects of miR-654-
5p on the biological characteristics of VSMCs induced by
PDGF-BB through binding the cells to target genes. TCF21
and MTAP were predicted and confirmed as the target genes
of miR-654-5p using the bioinformatics website, dual-
luciferase assay, and immunofluorescence. Studies showed
that aryl hydrocarbon receptor protein is localized in human
carotid atherosclerotic lesions [29] and that TCF21 can pro-
mote the expression of aryl hydrocarbon receptor and acti-
Vate the inflammatory gene expression program, thereby
increasing the risk of developing coronary artery diseases
[15]. In addition, studies demonstrated that MTAP is highly
expressed in atherosclerotic lesions, and that downregula-
tion of MTAP in macrophages may be achieved by a path-
way, which could inhibit TNF-α expression [19]. In this
study, we found by in vitro cell experiments that overexpress-
ion of TCF21 promoted the proliferation, migration, and
invasion of VSMCs. Overexpression of MTAP also pro-
moted the migration and invasion of VSMCs but did not
have much effect on cell proliferation. Furthermore, by
transfecting miR-654-5p mimic into cells, we found that
overexpression of miR-654-5p could inhibit the prolifera-
tion, migration, and invasion of TCF21, so we speculated that
miR-654-5p could pass the target gene, and inhibition
of TCF21 expression regulates PDGF-BB-induced prolifera-
tion and migration of VSMCs.

Studies showed that inhibiting miR-146 expression in rat
VSMCs significantly reduces cell proliferation and migration
[30]; moreover, overexpression of miR-214 in serum-free
VSMCs can greatly reduce the proliferation and migration
of VSMCs, while knocking down miR-214 noticeably
increases the proliferation and migration of VSMCs [31].
Studies on miR-654-5p are less conducted; however, Lu
et al. found that cell proliferation and metastasis were inhib-
ited after shRNA-654-5p was transfected into oral squamous
cell carcinoma cells [32]. miR-654-5p is highly expressed in
breast cancer cell, and functional analysis indicated that
miR-654-5p overexpression inhibits the growth and inva-
sion of MDA-MB-468 and BT-549 cells and induces apopto-
sis [27]. To further investigate the effect of miR-654-5p on
the biological properties of smooth muscle cells, ultrasound
microbubbles were used to deliver the miR-654-5p plasmid
into smooth muscle cells, and the results showed that Sono-
Vue microbubble ultrasound-miR-654-5p overexpression
inhibited VSMC proliferation, migration, and invasion, pro-
moted apoptosis, and inhibited TCF21 expression; thus, we
hypothesized that miR-654-5p is an important gene, which
affects the phenotypic transformation of smooth muscle
cells. Furthermore, we performed in vivo studies to deter-
mine the role of miR-654-5p by establishing a rat model of
carotid artery injury, and the results showed that SonoVue
microbubble ultrasound transmitted miR-654-5p into the
arterial wall and that arterial thrombosis and stenosis and
TCF21 were inhibited.

In conclusion, our findings suggested that miR-654-5p is an
important gene regulating VSMC phenotypic transfor-
mation, as it inhibits TCF21 expression and cell prolifera-
tion, invasion, and metastasis, thereby controlling arterial
thrombosis and stenosis.

Data Availability
All data were included in the manuscript.
Conflicts of Interest

The authors declared no conflict of interest.

References

[1] A. Gistera and G. K. Hansson, “The immunology of atherosclerosis,” Nature Reviews. Nephrology, vol. 13, no. 6, pp. 368–380, 2017.

[2] T. Miyazaki and A. Miyazaki, “Dysregulation of calpain proteolytic systems underlies degenerative vascular disorders,” Journal of Atherosclerosis and Thrombosis, vol. 25, no. 1, pp. 1–15, 2018.

[3] C. L. Song, J. P. Wang, X. Xue et al., “Effect of circular ANRIL on the inflammatory response of vascular endothelial cells in a rat model of coronary atherosclerosis,” Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, vol. 42, no. 3, pp. 1202–1212, 2017.

[4] Y. Xu, J. Xu, K. Ge, Q. Tian, P. Zhao, and Y. Guo, “Anti-inflammatory effect of low molecular weight fucoidan from _Saccharina japonica_ on atherosclerosis in apoE-knockout mice,” International Journal of Biological Macromolecules, vol. 118, pp. 365–374, 2018.

[5] N. Papadopoulos, G. Menikou, M. Yiannakou, K. Ioannides, and C. Damianou, "Evaluation of a small flat rectangular therapeutic ultrasonic transducer intended for intravascular use," Ultrasound, vol. 74, pp. 196–203, 2017.

[6] D. Giacoppo, R. Colleran, S. Cassese et al., “Percutaneous coronary intervention vs coronary artery bypass grafting in patients with left main coronary artery stenosis: a systematic review and meta-analysis,” JAMA Cardiology, vol. 2, no. 10, pp. 1079–1088, 2017.

[7] R. A. Montone, G. Niccoli, F. Vergni et al., “Endothelial dysfunction as predictor of angina recurrence after successful percutaneous coronary intervention using second generation drug eluting stents,” European Journal of Preventive Cardiology, vol. 25, no. 13, pp. 1360–1370, 2018.

[8] S. T. Haller, K. L. Evans, D. A. Folt, C. A. Drummond, and C. J. Cooper, “Mechanisms and treatments for renal artery stenosis,” Discovery Medicine, vol. 16, no. 90, pp. 255–260, 2013.

[9] T. Usui, T. Morita, M. Okada, and H. Yamawaki, "Histone deacetylase 4 controls neointimal hyperplasia via stimulating proliferation and migration of Vascular Smooth Muscle Cells," Hypertension, vol. 63, no. 2, pp. 397–403, 2014.

[10] X. L. Xiao, N. Hu, X. Z. Zhang et al., "Niclosamide inhibits vascular smooth muscle cell proliferation and migration and attenuates neointimal hyperplasia in injured rat carotid arteries," British Journal of Pharmacology, vol. 175, no. 10, pp. 1707–1718, 2018.

[11] R. M. Starke, N. Chalouhi, D. Ding et al., “Vascular smooth muscle cells in cerebral aneurysm pathogenesis,” Translational Stroke Research, vol. 5, no. 3, pp. 338–346, 2014.

[12] M. Lehners, H. Dobrowinski, S. Feil, and R. Feil, “cGMP signaling and VSMCs plasticity,” Journal of Cardiovascular Development and Disease, vol. 5, no. 2, p. 20, 2018.

[13] E. Raitoharju, N. Oksala, and T. Lehtimaki, “MicroRNAs in the atherosclerotic plaque,” Clinical Chemistry, vol. 59, no. 12, pp. 1708–1721, 2013.

[14] M. Li and J. Zhang, “Circulating microRNAs: potential and emerging biomarkers for diagnosis of cardiovascular and cerebrovascular diseases,” BioMed Research International, vol. 2015, Article ID 730555, 9 pages, 2015.

[15] J. B. Kim, M. Pjanic, T. Nguyen et al., “TCF21 and the environmental sensor aryl-hydrocarbon receptor cooperate to activate a pro-inflammatory gene expression program in coronary artery smooth muscle cells,” PLoS Genetics, vol. 13, no. 5, article e1006750, 2017.

[16] K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method,” Methods (San Diego, Calif.), vol. 25, no. 4, pp. 402–408, 2001.

[17] L. H. Lehmann, J. S. Rostosky, S. J. Buss et al., “Essential role of sympathetic endothelin A receptors for adverse cardiac remodeling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 37, pp. 13499–13504, 2014.

[18] C. Franco, G. Hou, P. J. Ahmad et al., “Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice,” Circulation Research, vol. 102, no. 10, pp. 1202–1211, 2008.

[19] L. M. Holdt, K. Sass, G. Gabel, H. Bergert, J. Thiery, and D. Teupser, “Expression of Chr9p21 genes CDKN2B (p15INK4b), CDKN2A (p16INK4a, p14ARF) and MTAP in human atherosclerotic plaque,” Atherosclerosis, vol. 214, no. 2, pp. 264–270, 2011.

[20] Y. Liu, X. Sun, Y. Wu et al., “Effects of miRNA-145 on airway smooth muscle cells function,” Molecular and Cellular Biochemistry, vol. 409, no. 1-2, pp. 135–143, 2015.

[21] Y. S. Wang, H. Y. J. Wang, Y. C. Liao et al., “MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation,” Cardiovascular Research, vol. 95, no. 4, pp. 517–526, 2012.

[22] S. Y. Eun, Y. S. Ko, S. W. Park, K. C. Chang, and H. J. Kim, "IL-1β enhances vascular smooth muscle cell proliferation and migration via P2Y1 receptor-mediated RAGE expression and HMGB1 release," Vascular Pharmacology, vol. 72, pp. 108–117, 2015.

[23] L. Meng, W. Xu, L. Guo, W. Ning, and X. Zeng, “Paenol inhibits the proliferation, invasion, and inflammatory reaction induced by TNF-α in vascular smooth muscle cells,” Cell Biochemistry and Biophysics, vol. 73, no. 2, pp. 495–503, 2015.

[24] J. Zhao, L. Jian, L. Zhang et al., “Knockdown of SCARAS5 inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration through suppression of the PDGF signaling pathway,” Molecular Medicine Reports, vol. 13, no. 5, pp. 4455–4460, 2016.

[25] P. Li, Y. Liu, B. Yi et al., “MicroRNA-638 is highly expressed in human vascular smooth muscle cells and inhibits PDGF-BB-induced cell proliferation and migration through targeting orphan nuclear receptor NOR1,” Cardiovascular Research, vol. 99, no. 1, pp. 185–193, 2013.

[26] Z. Qian, L. Zhang, J. Chen et al., “MiR-328 targeting PIM-1 inhibits proliferation and migration of pulmonary arterial smooth muscle cells,” The American Journal of Cancer Research, vol. 6, no. 2, pp. 522–532, 2016.

[27] B. Majem, A. Parrilla, C. Jiménez et al., “MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC,
WNT and AKT pathways,” *Oncogene*, vol. 38, no. 32, pp. 6035–6050, 2019.

[29] D. Wu, N. Nishimura, V. Kuo et al., “Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E-/- mice,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 31, no. 6, pp. 1260–1267, 2011.

[30] W. Xiong, S. Dong, J. Yuan, J. Li, J. Liu, and X. Xu, “MiRNA-146a promotes proliferation and migration of rat vascular smooth muscle cells in vitro in a nuclear factor-κB-dependent manner,” *Journal of Southern Medical University*, vol. 32, no. 2, pp. 270–273, 2012.

[31] T. A. Afzal, L. A. Luong, D. Chen et al., “NCK associated protein 1 modulated by miRNA-214 determines vascular smooth muscle cell migration, proliferation, and neointima hyperplasia,” *Journal of the American Heart Association*, vol. 5, no. 12, p. e004629, 2016.

[32] M. Lu, C. Wang, W. Chen, C. Mao, and J. Wang, “miR-654-5p targets GRAP to promote proliferation, metastasis, and chemoresistance of oral squamous cell carcinoma through Ras/MAPK signaling,” *DNA and Cell Biology*, vol. 37, no. 4, pp. 381–388, 2018.